Floatz logo

Siplizumab

Autoimmune Hepatitis

Elizabeth C. Vernamonoclonal_antibodyPhase 1Active
C
33/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
18/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Autoimmune Hepatitis cohort.

Asset / SponsorPhaseRating
Azathioprine
Xiaoli Fan
Phase 4BB
URSODEOXYCHOLIC ACID
West China Hospital
Phase 4BB
CYCLOSPORIN A
West China Hospital
Phase 4B
Jkb-122
TaiwanJ Pharmaceuticals Co., Ltd
Phase 2CCC
Orbcel-C
University of Birmingham
Phase 1/2CCC
METRONIDAZOLE
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
N/AD
Budesonide
Mayo Clinic
N/AD

Same molecule, other indications

Siplizumab is also rated in:

lymphomaDormant
CC
Indicative ·
42 / 100
View asset →
leukemiaDormant
CC
Indicative ·
42 / 100
View asset →
myelodysplastic syndromeDormant
C
Indicative ·
39 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →